EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

The clinical potential of HMGB1 for the risk assessment of severe checkpoint inhibitor pneumonitis: A prospective multicenter study (CS-Lung004)

Kakuhiro Yamaguchi, Shun Takao, Nobuhiro Kanaji, Tetsu Hirakawa, Naoko Matsumoto, Kozue Miyazaki, Tamio Okimoto, Chihiro Ando, Hisao Higo, Masaaki Yanai, Yasunari Nagasaki, Koji Kurose und 7 weitere

European Journal of Cancer · 2025

DOI: 10.1016/j.ejca.2025.115606 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Kakuhiro Yamaguchi und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Hiroshima University Hospital, Japan. Electronic address: yamaguchikakuhiro@gmail.com. Hauptthemen laut MEDLINE: HMGB1 Protein, Immune Checkpoint Inhibitors, Pneumonia, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HMGB1 ProteinImmune Checkpoint InhibitorsPneumoniaLung NeoplasmsCarcinoma, Non-Small-Cell LungHumansMaleFemaleProspective StudiesRisk AssessmentMiddle AgedAgedBiomarkers, TumorBiomarkers

Stichwörter der Autor:innen

HMGB1biomarkercheckpoint inhibitor pneumonitisrisk

Substanzen

HMGB1 ProteinImmune Checkpoint InhibitorsHMGB1 protein, humanBiomarkers, TumorBiomarkers

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Hiroshima University Hospital, Japan. Electronic address: yamaguchikakuhiro@gmail.com.
  • Department of Respiratory Internal Medicine, Hiroshima City Hiroshima Citizens Hospital, Japan.
  • Department of Internal Medicine, Division of Hematology, Rheumatology, and Respiratory Medicine, Faculty of Medicine, Kagawa University, Japan.
  • Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Japan.
  • Department of Respiratory Medicine, Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital, Japan.
  • Department of Respiratory Medicine, National Hospital Organization Higashi-Hiroshima Medical Center, Japan.

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Yamaguchi, K., Takao, S., Kanaji, N., Hirakawa, T., Matsumoto, N., Miyazaki, K., Okimoto, T., Ando, C., Higo, H., Yanai, M., Nagasaki, Y., Kurose, K., Watanabe, M., Oyama, K., Toyoda, Y., Ono, S., Tada, S., Iwamoto, H., & Hattori, N. (2025). The clinical potential of HMGB1 for the risk assessment of severe checkpoint inhibitor pneumonitis: A prospective multicenter study (CS-Lung004). European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115606

Vancouver

Yamaguchi K, Takao S, Kanaji N, Hirakawa T, Matsumoto N, Miyazaki K, et al. The clinical potential of HMGB1 for the risk assessment of severe checkpoint inhibitor pneumonitis: A prospective multicenter study (CS-Lung004). European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115606

BibTeX
@article{Yamaguchi2025,
  author = {Yamaguchi, Kakuhiro and Takao, Shun and Kanaji, Nobuhiro and Hirakawa, Tetsu and Matsumoto, Naoko and Miyazaki, Kozue and Okimoto, Tamio and Ando, Chihiro and Higo, Hisao and Yanai, Masaaki and Nagasaki, Yasunari and Kurose, Koji and Watanabe, Masako and Oyama, Kosuke and Toyoda, Yuko and Ono, Sachie and Tada, Shinpei and Iwamoto, Hiroshi and Hattori, Noboru},
  title = {The clinical potential of HMGB1 for the risk assessment of severe checkpoint inhibitor pneumonitis: A prospective multicenter study (CS-Lung004)},
  journal = {European Journal of Cancer},
  year = {2025},
  doi = {10.1016/j.ejca.2025.115606}
}
Kostenlos starten →